Ty 38c
Alternative Names: 38C - Tydock Pharma; Ty-38cLatest Information Update: 06 Sep 2023
At a glance
- Originator Tydock Pharma
- Class Antituberculars; Quinoxalines; Small molecules
- Mechanism of Action DprE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Tuberculosis
Most Recent Events
- 06 Sep 2023 Preclinical development is ongoing for Tuberculosis in Italy (Tydock Pharma website, September 2023)
- 06 Sep 2023 Chemical structure information added
- 28 Aug 2020 No recent reports of development identified for preclinical development in Tuberculosis in Italy